Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma

Abstract excerpt

Activating RAS mutations are found in a subset of fusion-negative rhabdomyosarcoma (RMS), and therapeutic strategies to directly target RAS in these tumors have been investigated, without clinical success to date. A potential strategy to inhibit oncogenic RAS activity is the disruption of RAS prenylation, an obligate step for RAS membrane localization and effector pathway signaling, through inhibition of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell Adhesion Molecules Research
• Share to Peptidase Inhibition and Analysis
• Share to Sarcoma Diagnosis and Treatment